Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 9,568 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genetics Clear all
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
View directory record Official record
Conditions
Healthy, Dermatitis, Atopic
Interventions
LY3844583, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Active, not recruiting Not applicable Interventional

Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction

NCT03533517
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Dilated
Interventions
AccuCinch® Ventricular Restoration
Device
Lead sponsor
Ancora Heart, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
18
States / cities
San Francisco, California • Atlanta, Georgia • Louisville, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 19, 2026, 2:55 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Fabry Disease Gene Therapy Study

NCT04040049
View directory record Official record
Conditions
Fabry Disease, Lysosomal Storage Diseases
Interventions
FLT190
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Active, not recruiting No phase listed Observational

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

NCT07062848
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
AI Toolkit for ATTR-CM Diagnosis
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
50 Years to 95 Years
Enrollment
1,500,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 19, 2026, 2:55 PM EDT
Withdrawn Phase 2 Interventional

Allograft for Sickle Cell Disease and Thalassemia

NCT02038478
View directory record Official record
Conditions
Sickle Cell Disease and Thalassemia
Interventions
Donor Stem Cell Transplantation
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones

NCT00381849
View directory record Official record
Conditions
Cystinuria, Nephrolithiasis, Calcium Oxalate
Interventions
Cystone, Sugar Pill (Placebo)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 19, 2026, 2:55 PM EDT
Recruiting No phase listed Observational

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

NCT06008938
View directory record Official record
Conditions
Hemophilia B
Interventions
HEMGENIX, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Recruiting No phase listed Observational

Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis

NCT06057714
View directory record Official record
Conditions
Cystic Fibrosis, Ventilatory Defect
Interventions
19F MRI
Combination Product
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Recruiting Phase 3 Interventional

Treatment of Chronic Thyroid Eye Disease With MHB018A

NCT07622121
View directory record Official record
Conditions
Thyroid Eye Disease, TED
Interventions
MHB018A injection, MHB018A injection Placebo
Drug
Lead sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Completed No phase listed Observational

The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest

NCT03079414
View directory record Official record
Conditions
Sudden Cardiac Death
Interventions
Invasive Electrophysiology Study
Procedure
Lead sponsor
Western University, Canada
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Not applicable Interventional

A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)

NCT01810614
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
ADPKD Diet
Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 19, 2026, 2:55 PM EDT
Completed No phase listed Observational

Neonatal CMV-Ganciclovir Follow-up Study

NCT00031421
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 14 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease

NCT01565616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Conditioning Regimen with Bone Marrow Transplant
Drug
Lead sponsor
Emory University
Other
Eligibility
16 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment for Improvement of Cellulite Appearance Using Form Applicator

NCT05882721
View directory record Official record
Conditions
Cellulite
Interventions
Sofwave
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
5
States / cities
Sacramento, California • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 19, 2026, 2:55 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

NCT03833921
View directory record Official record
Conditions
Prostate Cancer Metastatic, Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Martha Mims
Other
Eligibility
18 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

NCT00011414
View directory record Official record
Conditions
Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer
Interventions
Tariquidar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

NCT04154293
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
Isotretinoin, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
9 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Recruiting Not applicable Interventional

Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease

NCT06919224
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
mHealth app + booklets
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States

NCT04191824
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Timing of return of results
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
6,789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 19, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

NCT04912869
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 19, 2026, 2:55 PM EDT
Withdrawn No phase listed Observational

Genetic Influence on Statin Pharmacodynamics

NCT01569854
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 19, 2026, 2:55 PM EDT
Recruiting Phase 3 Interventional

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

NCT05432466
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
ACER-002 (celiprolol) 200 mg BID, Placebo BID
Drug
Lead sponsor
Acer Therapeutics Inc.
Industry
Eligibility
15 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 19, 2026, 2:55 PM EDT